Charles Schwab Investment Management Inc. Purchases 7,939 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Charles Schwab Investment Management Inc. boosted its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 0.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,184,609 shares of the biopharmaceutical company’s stock after purchasing an additional 7,939 shares during the period. Charles Schwab Investment Management Inc. owned about 0.77% of TG Therapeutics worth $27,708,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in TGTX. Price T Rowe Associates Inc. MD grew its holdings in TG Therapeutics by 6.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 85,603 shares of the biopharmaceutical company’s stock valued at $1,303,000 after purchasing an additional 5,015 shares during the last quarter. Cetera Advisors LLC bought a new position in TG Therapeutics during the 1st quarter valued at about $622,000. DekaBank Deutsche Girozentrale bought a new position in TG Therapeutics during the 1st quarter valued at about $58,000. Assenagon Asset Management S.A. bought a new position in TG Therapeutics during the 2nd quarter valued at about $8,698,000. Finally, Bank of New York Mellon Corp grew its stake in TG Therapeutics by 13.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 503,645 shares of the biopharmaceutical company’s stock worth $8,960,000 after acquiring an additional 59,523 shares in the last quarter. 58.58% of the stock is currently owned by institutional investors.

Insider Activity at TG Therapeutics

In related news, Director Sagar Lonial sold 5,000 shares of the stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $30.44, for a total transaction of $152,200.00. Following the completion of the sale, the director now owns 100,195 shares of the company’s stock, valued at $3,049,935.80. This represents a 4.75 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 10.50% of the stock is currently owned by corporate insiders.

TG Therapeutics Price Performance

Shares of TGTX opened at $33.88 on Thursday. The company has a 50 day moving average price of $27.03 and a 200-day moving average price of $22.56. TG Therapeutics, Inc. has a fifty-two week low of $12.84 and a fifty-two week high of $36.84. The stock has a market capitalization of $5.27 billion, a PE ratio of -337.50 and a beta of 2.25. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.01). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The business had revenue of $83.90 million during the quarter, compared to analysts’ expectations of $81.68 million. During the same period in the previous year, the company posted $0.73 EPS. TG Therapeutics’s revenue for the quarter was down 49.4% on a year-over-year basis. Equities analysts predict that TG Therapeutics, Inc. will post 0.17 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on TGTX shares. The Goldman Sachs Group upped their target price on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. HC Wainwright upped their target price on shares of TG Therapeutics from $49.00 to $55.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. TD Cowen started coverage on shares of TG Therapeutics in a research note on Tuesday, October 29th. They issued a “buy” rating and a $50.00 target price on the stock. JPMorgan Chase & Co. upped their target price on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research note on Monday, November 25th. Finally, B. Riley upped their target price on shares of TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $40.67.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.